Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib

Clinical trial NCT05252988 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05252988
Sponsor: Spanish Breast Cancer Research Group
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Early-stage Breast Cancer HER2 Positive Breast Cancer Hormone Receptor Positive

Start date: 2022-08-31
Primary completion: 2024-10-28
Enrollment: 177

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.